Antiretroviral treatment (ART) for HIV-positive patients has expanded rapidly in Asia over the last 10 years. Our study aimed to describe the time trends and risk factors for overall survival in patients receiving first-line ART in Asia.
Methods
We included HIV-positive adult patients who initiated ART between 2003–2013 (n=16,546), from seven sites across six Asia–Pacific countries. Patient follow-up was to May 2014. We compared survival for each country and overall by time period of ART initiation using Kaplan–Meier curves. Factors associated with mortality were assessed using Cox regression, stratified by site. We also summarized first-line ART regimens, CD4+ T-cell count at ART initiation, and CD4+ T-cell and HIV viral load testing frequencies.
Results
There were 880 deaths observed over 54,532 person-years of follow-up, a crude rate of 1.61 (95% CI 1.51, 1.72) per 100 person-years. Survival significantly improved in more recent years of ART initiation. The survival probability at 4 years follow-up for those initiating ART in 2003–2005 was 92.1%, 2006–2009 was 94.3% and 2010–2013 was 94.5% (P≤0.001). Factors associated with higher mortality risk included initiating ART in earlier time periods, older age, male sex, injecting drug use as HIV exposure and lower pre-ART CD4+ T-cell count. Concurrent with improved survival was increased tenofovir use, ART initiation at higher CD4+ T-cell counts and greater monitoring of CD4+ T-cells and HIV viral load.
Conclusions
Our results suggest that HIV-positive patients from Asia have improved survival in more recent years of ART initiation. This is likely a consequence of improvements in treatment, patient management and monitoring over time.
References
1.
MaR.Early ART improves life expectancy in HIV patients.Practitioner2012; 256: 5.
2.
McManusH., O'ConnorC.C., BoydM.Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy.PLoS ONE2012; 7: e48839.
3.
SabinC.A.Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?BMC Med2013; 11: 251.
4.
MocroftA., LedergerberB., KatlamaC.Decline in the AIDS and death rates in the EuroSIDA study: an observational study.Lancet2003; 362: 22–29.
5.
Antiretroviral Therapy Cohort Collaboration.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet2008; 372: 293–299.
6.
World Health Organization.Scaling up HIV/AIDS prevention, treatment and care: a report on WHO support to countries in implementing the ‘3 by 5′ initiative 2004–2005.Geneva, Switzerland: World Health Organization, 2006.
SrikantiahP., GhidinelliM., BachaniD.Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region.AIDS2010; 24Suppl 3: S62–S71.
10.
KazatchkineM., AtunR.HIV in Asia: universal access in sight.AIDS2010; 24Suppl 3: S1–S2.
11.
World Health Organization.ART Guidelines Committee Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2006 revision. (Accessed April 2015.) Available from http://www.who.int/hiv/pub/arv/adult/en/.
12.
MakinsonA., MoingV.L., KouanfackC., LaurentC., DelaporteE.Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings.Expert Opin Drug Saf2008; 7: 283–293.
13.
World Health Organization.ART Guidelines Committee Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2010 revision. (Accessed April 2015). Available from http://www.who.int/hiv/pub/arv/adult2010/en/index.html.
14.
World Health Organization.Consolidated guidelines on the use of Antiretroviral Drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: 2013. (Accessed October 2015.) Available from http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
GrinsztejnB., HosseinipourM.C., RibaudoH.J.Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the Phase 3 HPTN 052 randomised controlled trial.Lancet Infect Dis2014; 14: 281–290.
17.
DavisD.H., SmithR., BrownA., RiceB., YinZ., DelpechV.Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults.Age Ageing2013; 42: 520–526.
18.
GoldmanD.P., JudayT., SeekinsD., LinthicumM.T., RomleyJ.A.Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996–2009.Health Aff (Millwood)2014; 33: 362–369.
19.
RomleyJ.A., JudayT., SolomonM.D., SeekinsD., BrookmeyerR., GoldmanD.P.Early HIV treatment led to life expectancy gains valued at $80 billion for people infected in 1996–2009.Health Aff (Millwood)2014; 33: 370–377.
20.
BraitsteinP., BrinkhofM.W., DabisF.Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.Lancet2006; 367: 817–824.
PhuphuakratA., KiertiburanakulS., SungkanuparphS.Current status of HIV treatment in Asia and the Pacific region.Sex Health2014; 11: 119–125.
23.
KumarasamyN., KrishnanS.Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.Curr Opin HIV AIDS2013; 8: 586–590.
24.
KumarasamyN., MadhavanV., VenkateshK.K.High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.Clin Infect Dis2009; 49: 306–309.
25.
ZhouJ., KumarasamyN., DitangcoR.The TREAT Asia HIV Observational Database: baseline and retrospective data.J Acquir Immune Defic Syndr2005; 38: 174–179.
26.
Insight Start Study Group, LundgrenJ.D., BabikerA.G.Initiation of antiretroviral therapy in early asymptomatic HIV infection.N Engl J Med2015; 373: 795–807.
27.
ZhangF., DouZ., MaY.Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study.Lancet Infect Dis2011; 11: 516–524.
28.
van GriensvenJ., ZachariahR., RasschaertF., MugaboJ., AtteE.F., ReidT.Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.Trans R Soc Trop Med Hyg2010; 104: 148–153.
29.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA2004; 292: 191–201.
30.
FordN., CalmyA.Improving first-line antiretroviral therapy in resource-limited settings.Curr Opin HIV AIDS2010; 5: 38–47.
31.
ShubberZ., CalmyA., Andrieux-MeyerI.Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.AIDS2013; 27: 1403–1412.
32.
SwaminathanS., PadmapriyadarsiniC., VenkatesanP.Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.Clin Infect Dis2011; 53: 716–724.
33.
CornellM., GrimsrudA., FairallL.Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007.AIDS2010; 24: 2263–2270.
34.
BoulleA., Van CutsemG., HilderbrandK.Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.AIDS2010; 24: 563–572.
35.
BoulleA., OrrelC., KaplanR.Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.Antivir Ther2007; 12: 753–760.
36.
HermansS.M., van LethF., ManabeY.C., HoepelmanA.I., LangeJ.M., KambuguA.Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.HIV Med2012; 13: 337–344.
37.
LimaV.D., HoggR.S., HarriganP.R.Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.AIDS2007; 21: 685–692.
38.
PattersonS., CesconA., SamjiH.Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.BMC Infect Dis2015; 15: 274.
39.
MontanerJ.S., LimaV.D., BarriosR.Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.Lancet2010; 376: 532–539.
40.
SamjiH., CesconA., HoggR.S.Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.PLoS ONE2013; 8: e81355.
41.
Antiretroviral Therapy Cohort Collaboration.Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet2008; 372: 293–299.
42.
BrinkhofM.W., Pujades-RodriguezM., EggerM.Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.PLoS ONE2009; 4: e5790.
